866-997-4948(US-Canada Toll Free)

Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Review, H2 2013

Published By :

Global Markets Direct

Published Date : Oct 2013

Category :

Oncology

No. of Pages : 57 Pages


Global Markets Directs, \'Metastatic Hepatocellular Carcinoma (HCC) Pipeline Review, H2 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Hepatocellular Carcinoma (HCC), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metastatic Hepatocellular Carcinoma (HCC). Metastatic Hepatocellular Carcinoma (HCC) Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Metastatic Hepatocellular Carcinoma (HCC).
  • A review of the Metastatic Hepatocellular Carcinoma (HCC) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Metastatic Hepatocellular Carcinoma (HCC) pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Metastatic Hepatocellular Carcinoma (HCC).
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Metastatic Hepatocellular Carcinoma (HCC) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Metastatic Hepatocellular Carcinoma (HCC) Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Metastatic Hepatocellular Carcinoma (HCC) 7
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics under Development by Companies 9
Mid Clinical Stage Products 10
Comparative Analysis 10
Early Clinical Stage Products 11
Comparative Analysis 11
Discovery and Pre-Clinical Stage Products 12
Comparative Analysis 12
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics - Products under Development by Companies 13
Companies Involved in Metastatic Hepatocellular Carcinoma (HCC) Therapeutics Development 14
F. Hoffmann-La Roche Ltd. 14
AstraZeneca PLC 15
Eli Lilly and Company 16
MedImmune LLC 17
Active Biotech AB 18
Alnylam Pharmaceuticals, Inc 19
Metastatic Hepatocellular Carcinoma (HCC) - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Drug Profiles 25
RG-7686 - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
cixutumumab - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
dusigitumab - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
tasquinimod - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
ALN-VSP - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
UPO-901 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
OREG-5 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
OREG-6 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics - Drug Profile Updates 38
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics - Discontinued Products 45
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics - Dormant Products 46
Metastatic Hepatocellular Carcinoma (HCC) - Product Development Milestones 47
Featured News & Press Releases 47
Oct 09, 2013: Active Biotech Receives Tasquinimod Milestone Payment from Ipsen for 10TASQ10 Study 47
Oct 08, 2013: Tekmira Provides Corporate Update On Oncology Product Candidate TKM-PLK1 47
Oct 02, 2013: MultiCell Technologies Expands Scope of Research Agreement for the Treatment of Liver Cancer 49
Oct 01, 2013: U.S. FDA Grants Orphan Drug Designation to Delcath Systems for Use of Melphalan Hydrochloride in HCC 49
Sep 09, 2013: Data Supporting Bavituximab\'s Immunotherapy Mechanism of Action Published in the Peer-Reviewed AACR Journal Cancer Immunology Research 50
Aug 22, 2013: Cellular Biomedicine Announces Completion of Patient Enrollment for Phase I Clinical Trial for Liver Cancer 51
Jul 30, 2013: Mirna Therapeutics Announces Important Expansion of microRNA Patent Portfolio 51
Jul 11, 2013: Celsion Announces ThermoDox HEAT Study Findings To Be Presented at the International Liver Cancer Association 2013 Annual Conference in Washington, DC on September 14, 2013 52
Jun 20, 2013: Celsion Announces Presentation Of ThermoDox HEAT Study Findings At 2013 ECIO 52
May 30, 2013: Celsion To Present Data On ThermoDox HEAT Study At 2013 ECIO 53

Appendix 55
Methodology 55
Coverage 55
Secondary Research 55
Primary Research 55
Expert Panel Validation 55
Contact Us 56
Disclaimer 56

List of Table


Number of Products Under Development for Metastatic Hepatocellular Carcinoma (HCC), H2 2013 7
Products under Development for Metastatic Hepatocellular Carcinoma (HCC) - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 9
Comparative Analysis by Mid Clinical Stage Development, H2 2013 10
Comparative Analysis by Early Clinical Stage Development, H2 2013 11
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 12
Products under Development by Companies, H2 2013 13
F. Hoffmann-La Roche Ltd., H2 2013 14
AstraZeneca PLC, H2 2013 15
Eli Lilly and Company, H2 2013 16
MedImmune LLC, H2 2013 17
Active Biotech AB, H2 2013 18
Alnylam Pharmaceuticals, Inc, H2 2013 19
Assessment by Monotherapy Products, H2 2013 20
Assessment by Stage and Route of Administration, H2 2013 22
Assessment by Stage and Molecule Type, H2 2013 24
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics - Drug Profile Updates 38
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics - Discontinued Products 45
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics - Dormant Products 46

List of Chart


Number of Products under Development for Metastatic Hepatocellular Carcinoma (HCC), H2 2013 7
Products under Development for Metastatic Hepatocellular Carcinoma (HCC) - Comparative Analysis, H2 2013 8
Products under Development by Companies, H2 2013 9
Mid Clinical Stage Products, H2 2013 10
Early Clinical Stage Products, H2 2013 11
Discovery and Pre-Clinical Stage Products, H2 2013 12
Assessment by Monotherapy Products, H2 2013 20
Assessment by Route of Administration, H2 2013 21
Assessment by Stage and Route of Administration, H2 2013 22
Assessment by Molecule Type, H2 2013 23
Assessment by Stage and Molecule Type, H2 2013 24

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *